This uncertainty is reflected by the diverse positions of drug regulatory agencies, with the same SGLT2i being either approved an adjunct to insulin in patients with T1DM inadequate glycemic control [9,10], or approved with restriction to patients with a body mass index (BMI) ≥27 kg/m2 [11–13] despite the lack of data regarding the risk of DKA in overweight individuals, or rejected because of the risk of DKA deemed excessively high [14,15]. This evidence concerns the gene INS and type 1 diabetes mellitus.